Modulation of mucosal/systemic antibody response after sublingual immunotherapy in mite-allergic children
Article first published online: 2 DEC 2013
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Pediatric Allergy and Immunology
Volume 24, Issue 8, pages 752–761, December 2013
How to Cite
Modulation of mucosal/systemic antibody response after sublingual immunotherapy in mite-allergic children. Pediatr Allergy Immunol 2013: 24: 752–761., , , , , , , , , , .
- Issue published online: 13 DEC 2013
- Article first published online: 2 DEC 2013
- Manuscript Accepted: 6 OCT 2013
- CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Brasília, DF)
- CNPq (Conselho Nacional de Pesquisa e Desenvolvimento, Brasília, DF)
- FAPEMIG (Fundação de Amparo à Pesquisa do Estado de Minas Gerais, Belo Horizonte, MG)
- Dermatophagoides pteronyssinus ;
- sublingual immunotherapy;
- IgE antibody;
- IgG1/IgG4 subclasses;
- salivary IgA antibody
There have been no data on sublingual immunotherapy (SLIT) in Brazilian patients sensitized to house dust mites. This study aimed to evaluate the mucosal/systemic antibody response changes and clinical efficacy after SLIT using Dermatophagoides pteronyssinus (Dpt) allergens with or without bacterial extracts in mite-allergic Brazilian children.
Patients with allergic rhinitis and asthma were selected for a double-blind, placebo-controlled trial randomized to three groups: DPT (Dpt extract, n = 34), DPT+MRB (Dpt plus mixed respiratory bacterial extracts, n = 36), and Placebo (n = 32). Total symptom and medication scores for rhinitis/asthma, skin prick test (SPT) to Dpt, and measurements of Dpt-, Der p 1-, Der p 2-specific serum IgE, IgG4, IgG1, and specific salivary IgA were evaluated at baseline and after 12 and 18 months of treatment.
A significant long-term decline in total symptom/medication scores was observed only in active groups (DTP and DPT+MRB). There was no significant change in SPT results in all groups. SLIT using Dpt allergen alone induced increased levels of serum IgG4 to Dpt, Der p 1, and Der p 2, serum IgG1 and salivary IgA to Dpt and Der p 1. SLIT with Dpt plus bacterial extracts was able to decrease IgE levels, particularly to Der p 2, to increase salivary IgA levels to Der p 1, but had no changes on specific IgG4 and IgG1 levels.
All children undergoing SLIT showed clinical improvement, but a long-term reduction in symptom/medication scores with modulation of mucosal/systemic antibody responses were seen only in active groups (DPT and DPT+MRB).